What to expect in this blog
1. Industrial pain and challenges
- Thriving but also challenging life science landscape
2. Why can’t you do drug development all alone
- Independent of the development stage your compound is in, it takes a ‘Tiger Team’ to rocket it to the next step
3. A dynamic and agile strategy to tackle the challenges
- In 2013, 2 Bridge is Born
- From NASA’s Tiger Team to drug development: How 2 Bridge aims for the moon in pharma innovation
4. Benefits of working with a Cross-Functional Tiger Team
- If you are a startup, you gain…
- If you are an investor, you benefit from…
Thriving, but also challenging life science landscape
The life sciences sector is experiencing rapid growth, with booming R&D efforts driving innovation in drug development. However, small biotech companies face significant challenges in this ever-changing landscape.
- Limited funding and resources force them to stretch budgets over long, uncertain development cycles, making tough investment decisions based on limited data.
- The multidisciplinary nature of drug development adds complexity, as small companies struggle to integrate diverse expertise.
- Competing with larger players is tough, and a single failed trial can be financially devastating, making agility and strategic thinking essential for survival.
- The rapid pace of innovation, evolving regulatory requirements, and intense competition further complicate this already difficult environment. Drug development is no longer a task for any one group or discipline, but a collective effort that requires agility, adaptability, and strategic foresight.
Independent of the development stage your compound is in, it takes a ‘Tiger Team’ to rocket it to the next step
For every submission, there are:
- A multitude of scenarios
- Project & functional budgets
- Milestones and key deliverables
which need to be carefully balanced according to the project needs.
And each submission needs experts in different functions:
- Translational sciences
- Preclinical development
- CMC
- Quality
- Regulatory
- Clinical & Clinical Operations
All professionals involved in drug development play a critical role in ensuring the drug is discovered, developed, tested, manufactured, and delivered safely and effectively.
In 2013, 2 Bridge was born
After years of working together in a multidisciplinary R&D team, the founding partners of 2 Bridge saw both the challenges and opportunities in the field. This inspired them to create a company with a cross-functional team focused on helping businesses overcome these hurdles and bring science to life.
From NASA’s Tiger Team to drug development – How 2 Bridge aims for the moon in pharma innovation
The term “Tiger Team” was popularized by NASA during the Apollo 13 mission. There, it referred to a cross-functional group of experts from different fields and backgrounds brought together to work on a specific goal or to solve a critical problem. At 2 Bridge, we aim at the moon and propel start-ups forward with our multi-disciplinary subject matter experts (SME). Guided by experienced pharma leaders, they will streamline your compound’s (pre)clinical development, whether it be a small molecule, ASO, ATMP, ADC, peptide, or protein. We strongly believe and testify that the strength of a strong, trusted team that works in a synergistic ‘Tiger Team” manner, could be of great value to other companies engaged in drug development; whether start-ups, academic centers, or even mid-to-large-sized pharmaceutical companies.
When working with a cross-functional team, like a 2 Bridge Tiger Team, you get the option to include the right functional experts at the right time.
If you are a startup, you gain…
- Rapid access to industry-experienced R&D experts and avoiding obvious pitfalls in the early stages
- Flexible support along varying R&D needs resulting in lower costs as compared to full-time hires
- Seamless integration of 2 Bridge experts into the existing team
- Transparent and competitive fee structure allowing focus on R&D activities
If you are an investor, you benefit from…
- Rapid execution of R&D plans upon funding – no delay in hiring & onboarding
- Guidance by independent experts to avoid unnecessary risk-taking and project creeping
- Facilitated transition to full-time management and shaping the company for exit options
- No dilution of shareholding thereby leveraging early-stage investment
The science of healthcare product development is our core expertise and building a thriving biotech company around this foundation is our second nature.